Releases

Date	Title and Summary
Mar 08, 2019 9:01 AM CET Corporate Releases	Lundbeck appoints Keld Flintholm Jørgensen as EVP and Chief Business Officer
Feb 28, 2019 9:15 AM CET Corporate Releases	Notice of Annual General Meeting
Feb 18, 2019 9:46 AM CET Corporate Releases	Lundbeck increases its share capital by 5,631 shares (0.0028 % of outstanding shares) as a result of exercise of employee warrants
Feb 14, 2019 3:00 PM CET Corporate Releases	Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
Feb 05, 2019 7:52 AM CET Corporate Releases	Annual Report 2018 for H.Lundbeck A/S
Feb 05, 2019 7:40 AM CET Corporate Releases	Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018
Jan 22, 2019 6:32 AM CET Corporate Releases	Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck
Jan 04, 2019 8:00 AM CET Press Releases	Lundbeck initiates phase II-study of potential new treatment of schizophrenia

Choose region and then country